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74 Gy without interruption and without missing any doses of q2wk B. 
Two had Gr 3 esophagitis. Only 2 of 5 from Cohort I have started (and 
completed) consolidation BEr (2 had persisitent Gr 3 esophagitis and 1 
early death due to disease progression). In Cohort II, 3 of 5 have com-
pleted I + C therapy (all doses of B were delivered during C therapy; 2 
are currently under treatment).
Conclusions: Preliminarily, we conclude that 1) Incorporation of B 
into this treatment paradigm is safe, 2) Esophagitis remains the primary 
toxicity and appeared to be unusually persistent in our initial cohort, 3) 
Accrual to Cohort III is ongoing.
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Background: Induction chemotherapy and radiotherapy is the treat-
ment base for locally advanced non-small cell lung cancer (NSCLC). 
However, both loco-regional and distant failure is frequent. Attempts to 
improve the loco-regional control were made in three separate phase II 
studies in Swedish University Hospitals, where accelerated radiother-
apy or concomitant daily or weekly chemotherapy with conventional 
radiotherapy were tested. Comparatively good results from these stud-
ies lead to this national randomized phase II study, the RAKET-study, 
where the different concepts were investigated on a wider basis for 
further phase III studies. 
Methods: Inoperable stage III non-small cell lung cancer patients in 
good performance status (PS<2) were equally randomized to either of 
three arms A, B or C in eight institutions. All arms started with two 
cycles of induction chemotherapy: Paclitaxel 200 mg/m2 and carbo-
platin AUC6. Arm A: A third identical cycle was given concomitant 
with start of accelerated radiotherapy, 1.7 Gy BID to 64.6 Gy in 4.5 
weeks. Arm B consisted of daily concomitant paclitaxel 12 mg/m2 with 
conventionally fractionated radiotherapy: 2 Gy daily to 60 Gy in 6 
weeks. Arm C: Weekly concomitant paclitaxel 60 mg/m2 and identical 
radiotherapy to 60 Gy. Primary endpoint: TTP, Secondary: OS, toxicity, 
QL and relapse pattern.
Results: Between June 2002 and May 2005 152 patients were ran-
domized and 148 evaluable: 76 men and 72 women, median age 62 
years (43-78), 55% had Performance Status 0 and 45% PS 1. Mean 
pretreatment pulmonary function: FEV1:2.1 L (0.8-4.5). Thirty-four 
percent had stage IIIa and 66% IIIb. Histology: Adenocarcinoma 48%, 
squamous cell carcinoma 32% and 20% non-small cell carcinoma. The 
three arms were well balanced. 
Median time to progression: 8.9, 10.3 and 9.1 moths for arm A, B and 
C, respectively. Median survival: 17.7, 17.8 and 20.6 months for A, B 
and C. Two-year overall survival: 41%, 43% and 45% respectively for 
A, B and C.
Conclusions: Treatment results are quite equal by intensifying the 
loco-regional treatment either by accelerated fractionated radiotherapy 
or daily or weekly concomitant chemo-radiotherapy. Toxicity and qual-
ity of life data, that soon will be completed and reported at the meeting, 
will be of great importance for further decisions. 
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Background: The recommended treatment in inoperable stage III 
non-small cell lung cancer (NSCLC) is concurrent chemoradiotherapy 
(CCRT). Recent phase II trial for the consolidation chemotherapy with 
docetaxel after CCRT gave promising data, but the survival beneﬁt of 
consolidation chemotherapy after CCRT has not been determined yet. 
This study is multinational, multicenter, phase III randomized trial to 
determine the efﬁcacy of consolidation chemotherapy with docetaxel 
and cisplatin after completing CCRT with the same chemotherapeutic 
agents in stage III inoperable NSCLC. Here we report the preliminary 
data for feasibility and safety analysis of this trial.
Methods: Patients with inoperable stage III NSCLC were eligible. N2 
or N3 disease was conﬁrmed by PET or pathology. Eligible patients 
were randomized to either observation or consolidation chemotherapy 
arm. During CCRT, docetaxel (20 mg/m2) and cisplatin (20 mg/m2) 
were administered every week for 6 times and a total dose of 66 Gy of 
thoracic radiation therapy was given in 33 fractions. In consolidation 
arm, the patients were further treated for 3 cycles with docetaxel and 
cisplatin (35 mg/m2 on day 1 and 8, every 3 weeks).
Results: Eighty one patients were enrolled from May 2005 to early 
January 2007. Seventy eight patients were evaluable. Thirty six patients 
were randomized to CCRT alone and 42 patients to CCRT with con-
solidation. Patients’ characteristics were similar in both arms. CCRT 
was generally well tolerated. During CCRT, frequent non-hematologic 
toxicities of all grades were anorexia(55%), nausea(60%), asthe-
nia(29%), alopecia(37%), and esophagitis(83%). Grade 3-4 toxicities 
were rare and radiation-associated esophagitis was observed in 10.4% 
of patients. Hematololgic toxicities during CCRT were mild and grade 
3-4 toxicities were observed in 4 patients The toxicities, which led 
to death, occurred in 4 patients and all those toxicities were probably 
related to CCRT. Eighty percent of patients who were randomized to 
consolidation arm received consolidation chemotherapy and 78% of 
patients who started consolidation chemotherapy completed at least 
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2 cycles of chemotherapy. Common non-hematologic toxicities of all 
grades during consolidation chemotherapy were anorexia(45%), alope-
cia(41%), asthenia(35%), and esophagitis(41%). Hematologic toxicities 
were mild. Although Grade 3-4 neutropenia occurred in 5 cycles out of 
65 cycles, there was no treatment-related mortality 
Conclusions: These results suggest that CCRT with weekly docetaxel 
and cisplatin is feasible and consolidation chemotherapy with same 
agents after CCRT is also well tolerated. Further data will be updated 
on presentation.
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Background: Concurrent chemoradiotherapy (chemoRT) is the pre-
ferred treatment for patients with unresectable stage III NSCLC. Lim-
ited safety information is available on the use of concurrent docetaxel, 
carboplatin and thoracic RT. We report the safety information on the 
initial 100 patients (pts) treated with this chemoRT as part of an ongo-
ing US randomized web-based phase III trial (D0410) evaluating the 
role of erlotinib/placebo following this concurrent chemoRT treatment. 
The sample size is 400 pts and the primary endpoint is progression-free 
survival.
Methods: Pts with unresectable pathologically conﬁrmed stage III 
NSCLC are randomized to receive either erlotinib 150 mg or placebo 
orally daily for 2 years following concurrent chemoRT with docetaxel 
20 mg/m2, carboplatin AUC=2 intravenously weekly for 6 wks with 
thoracic RT of at least 61 Gy in 33 fractions over 6.5 weeks. The 
planned total lung volume exceeding 20 Gy (V20) was less than 32%. 
Only the chemoradiation safety information is being reported. This data 
was reviewed by an independent safety and data monitoring committee.
Results: Pt characteristics; 59% males, median age 69 years (range 38 
to 86), 21% adenocarcinoma, 48% squamous cell, 94% ECOG PS0-1, 
49% stage IIIA, 15% weight loss ≥ 10%. Of 600 planned chemotherapy 
treatments, 500 were administered (93 wk 1, 86 wk 2, 83 wk 3, 82 wk 4, 
80 wk 5, 76 wk 6). There were 27 chemotherapy dose reductions; most 
commonly for esophagitis (8), neutropenia (5), renal dysfunction (3), hy-
persensitivity (2). There were no treatment-related deaths. There were 28 
grade 3 and 3 grade 4 treatment-related adverse events. The most com-
mon grade 3/4 events were esophagitis (7), fatigue (3), dysphagis (2), 
odynophagia (2), neutropenia (1), thrombocytopenia (1), dematitis (1).
Conclusions: This concurrent chemoradiation regimen appears to be 
safe. Enrollment to the phase III trial continues. There is a planned 
interim efﬁcacy evaluation at 150 events (deaths or disease progres-
sion). Funded in part by Sanoﬁ-Aventis, Genentech, and OSI Pharma-
ceuticals.
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Purpose and Objective(s): To assess the incidence and severity of 
acute esophageal reactions from concurrent chemotherapy and 3-di-
mensional proton beam therapy (PBT) in the context of previous results 
with concurrent chemotherapy and 3-dimensional photon therapy (XT) 
for NSCLC.
Materials and Methods: Twenty-ﬁve consecutive patients with NSC-
CL (stages IIB [1], IIIA [8], IIIB [8], IV [2], post-operative recurrent 
[6], underwent PBT and concurrent chemotherapy with curative intent 
on IRB approved protocols. Chemotherapy was platinum-based in all 
patients, most frequently carboplatin/paclitaxel (16 patients). There 
were 16 males/9 females ranging in age from 49 to 81 years (median 
67 years). Histopathologic diagnosis was squamous cell carcinoma in 9 
and non-squamous in 16 patients. All patients were evaluable for acute 
(< or = 90 days from ﬁrst treatment) reactions. Toxicity was based on 
NCI common toxicity criteria vs. 3.0. XT comparisons were based on 
published data from our institution (215 patients) (Wei X et al, Int J 
Radiat Oncol Biol Phys 2006)
Results: Total doses with PBT ranged from 63 cobalt-gray equivalent 
(CGE) (using RBE of 1.1 vs. cobalt gamma rays) to 74 CGE (60-69.6 
Gy with XT) in 33 to 37 fractions (30-58 fractions with XT). The 
median total dose was 74 CGE vs. 63 Gy for XT. Acute esophageal 
reactions were observed in 60% of PBT patients (200 of 215/93% with 
XT). Seven (28%) of patients had grade 2 esophageal reactions (97 of 
215/45.1% with XT). Four (16%) of patients had grade 3 esophageal 
reactions (43 of 215/20.0% with XT). No patient had a grade 4 reaction 
(1of 215/0.5% with XT).
Conclusions: Proton beam therapy permitted higher total doses (17%+) 
with concurrent chemotherapy yet were associated with reduced 
esophageal reactions compared with 3-dimensional conformal photon 
therapy.
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